Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Micro-dose glucagon effects on continuous glucose monitoring performance in type 1 diabetes
2022-000800-37Phase 2Terminated
- Sponsor
- St. Olavs University Hospital
- Start
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of glucagon in diabetes mellitus type 1 (T1D) (2 arms), sponsored by St. Olavs University Hospital. Primary endpoint: Time to detect 1.0 mmol/L postprandial glucose increase. Started Jul 2022; status: terminated.
02
Drugs
glucagon
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2022-000800-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000800-37.